Agree Realty Supports Innovative Turbine-AstraZeneca Partnership Revolutionizing Cancer Therapy Development
- Turbine collaborates with AstraZeneca to enhance antibody-drug conjugate (ADC) discovery using AI-driven predictive modeling.
- The partnership aims to streamline ADC development and improve patient outcomes through efficient screening strategies.
- Turbine's Simulated Cell™ platform focuses on optimizing drug response predictions for innovative cancer therapies.
Innovative Collaborations in Cancer Therapy: Turbine and AstraZeneca's Game-Changing Partnership
In an exciting development within the biopharmaceutical industry, Turbine announces a strategic collaboration with AstraZeneca aimed at revolutionizing the discovery process of antibody-drug conjugates (ADCs). This partnership is set to harness Turbine's cutting-edge platform, which utilizes artificial intelligence to predict response mechanisms and optimize ADC positioning. By minimizing the reliance on extensive cell line screenings, the collaboration targets a significant bottleneck in ADC development, a specialized cancer therapy designed to directly deliver potent medications to cancer cells. The initiative promises to enhance the efficiency and efficacy of ADC discovery, thereby improving outcomes for patients battling cancer.
The collaboration introduces a lab-in-the-loop approach, enabling Turbine's Simulated Cell™ platform to recommend a focused selection of cell lines for testing based on AstraZeneca's ADC datasets. This innovative strategy is designed to predict outcomes more accurately by analyzing mechanisms of resistance and gene expression changes in patient-derived xenografts (PDXs). Daniel Veres, MD, PhD, Chief Scientific Officer and Co-Founder of Turbine, stresses the critical need for a more efficient screening strategy to identify successful ADC combinations. By integrating advanced predictive modeling into the drug discovery process, the partnership aims to overcome traditional hurdles and enhance the clinical relevance of ADC therapies.
With a decade of experience in creating virtual disease models, Turbine positions itself as an invaluable asset in drug response prediction. The collaboration with AstraZeneca not only aims to streamline the ADC development process but also seeks to ensure that impactful experiments are prioritized during drug discovery. As the biopharmaceutical landscape evolves, such innovative partnerships will play a pivotal role in enhancing therapeutic options for patients, particularly in the challenging field of oncology.
In related news, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. recently announces the approval of its ADC sacituzumab tirumotecan (sac-TMT) by the National Medical Products Administration for treating adult patients with advanced non-small cell lung cancer (NSCLC) who have progressed following prior EGFR-tyrosine kinase inhibitor (TKI) therapy. This approval marks a significant milestone as sac-TMT is the first ADC globally to demonstrate an overall survival benefit over standard chemotherapy in this patient demographic.
Related Cashu News

Lamar Advertising Co Moves to Value Indices Amid Shift in Investment Strategies
Lamar Advertising Co (Ticker: LAMR) has recently undergone a significant change in its market classification by being added to several Russell value and defensive indices. This inclusion reflects a sh…

Alexandria Real Estate Equities Advances Corporate Responsibility and Strengthens Its Position in Life Sciences
Alexandria Real Estate Equities (ARE) has made significant strides in enhancing its corporate responsibility efforts, as detailed in its recently published 2025 Corporate Responsibility Report. The re…

Healthpeak OP LLC Achieves Key Index Inclusion, Boosting Investor Interest and Trading Activity
Healthpeak OP LLC (Ticker: DOC) leverages significant market developments to reinforce its position in the real estate investment trust sector through strategic index inclusion, which may reshape inve…

Public Storage Boosts Financial Flexibility with New Credit Facility and Commercial Paper Program
Public Storage (Ticker: PSA) enhances its financial flexibility with a new unsecured credit facility and commercial paper program. Strategic Financial Innovations The company announces the closure of…

